Stock Analysis
Becton, Dickinson and Company (BDX) Stock Analysis
Becton, Dickinson and Company (BDX) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Becton, Dickinson and Company (BDX) currently has an AIQ Score of 48/100, indicating a neutral setup. Value is the strongest factor at 63/100. Momentum is the weakest current factor at 37/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
BDX at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $177.85 |
| AIQ Score | 48/100 |
| Overall View | Neutral |
| Technical Analysis Consensus | Sell |
| Market Cap | $51.56B |
| P/E Ratio | 14.39 |
| Forward P/E | — |
| EPS | $1.37 |
| Revenue TTM | $4.98B |
| Dividend Yield | 0.02% |
| Beta | 0.26 |
| Volume | 1.6M |
| 52-week range | $140.11-$213.08 |
| RSI 14 | 19.31 |
| 50-Day SMA | $171.96 |
| 200-Day SMA | $171.45 |
| Analyst Price Target | $185.00 |
| Next Earnings | Nov 5, 2026 |
BDX
OverviewBDX Stock Analysis Summary
Becton, Dickinson and Company (BDX) currently has an AIQ Score of 48/100, indicating a neutral setup. Value is the strongest factor at 63/100. Momentum is the weakest current factor at 37/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a neutral regime, BDX has AIQ Score of 48/100 with Value base of 63/100 and fading Momentum at 37/100. Wait for component alignment before adding exposure.
Value (63/100) leads while Momentum (37/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · 0.81% stock move · BDX classified in Medical - Instruments & Supplies.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is BDX Bullish or Bearish Right Now?
BDX currently has a neutral overall setup. Value is the strongest factor at 63/100, while Momentum is weakest at 37/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.
- - Price is +3.43% above its 50-day SMA.
- - Analyst target implies +4.02% upside from the latest quote.
- - Momentum is weak at 37/100.
- - Technical consensus has more sell votes than buy votes (25 vs 18).
Current Consensus
BDX's Technical Analysis Consensus is currently Sell, with 18 buy, 2 neutral, and 25 sell votes. BDX's 14-day RSI is 19.31, which places the stock in an oversold momentum range. BDX's beta is 0.26, indicating lower market sensitivity than the broad market.
What Changed in BDX?
Recent score-change history is not available in the current snapshot. These are the latest market-close scores instead.
What Would Change the BDX Outlook?
The current neutral outlook could improve if AIQ moves above 70, momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 40, price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ > 70, RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 40, RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
BDX Decision Framework
Public evidence layers, setup checks, and risk context for Becton, Dickinson and Company.
Becton, Dickinson and Company (BDX) Stock Analysis
Becton, Dickinson and Company has an AIQ Score of 48/100 in a Neutral regime. Value is strongest at 63/100. Beta is 0.26, below market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | BDX is in a Neutral AIQ regime with score 48/100. |
| Signal Conflict | The primary conflict is that value leads at 63/100 while momentum lags at 37/100. |
| Factor Evidence | Momentum 37/100 · Value 63/100 · Quality 44/100 · Risk 47/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Value is the strongest factor at 63/100.
Momentum is 37/100 and RSI (14) is 19.3.
BDX is in a Neutral regime at 48/100.
Risk factor is 47/100 with beta 0.26 and annual volatility 30.6%.
Current conflict: value leads at 63/100 while momentum lags at 37/100.
BDX Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
BDX Fundamentals
BDX valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
BDX Technical Analysis
BDX technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
BDX Stock Catalysts
Track BDX earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
BDX Dividend Analysis
BDX dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
BDX Financial Data
BDX revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
BDX Risk Analysis
BDX volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
BDX Stock News
BDX stock news, market tone, recent headlines, and catalyst context.
BDX vs Medical Devices Peers
Current peer cohort: BDX · BSX · COO · CRL · DXCM. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| BDX Current stock | 48/100 | 63/100 | 37/100 | 47/100 | -0.16 | 30.60% | Current |
| BSX Boston Scientific | 50/100 | 58/100 | 23/100 | 42/100 | -2.28 | 37.90% | BDX vs BSX |
| COO Cooper Companies | 46/100 | 59/100 | 20/100 | 43/100 | -0.67 | 32.21% | BDX vs COO |
| CRL Charles River Labs | 38/100 | 42/100 | 35/100 | 50/100 | 1.45 | 45.98% | BDX vs CRL |
| DXCM Dexcom | 53/100 | 28/100 | 41/100 | 60/100 | 0.33 | 41.18% | BDX vs DXCM |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Sep 11, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts7 recent quarterly periods are available for review.
Checked Sep 12, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Jun 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching BDX
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for BDX
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
BDX Stock FAQ
What is BDX stock price today?
Becton, Dickinson and Company's current stock price is $177.85. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is BDX bullish or bearish right now?
BDX's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is BDX's market cap?
BDX's market cap is $51.56B based on the latest completed market-close snapshot from Sep 11, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is BDX's current P/E ratio?
BDX's current P/E ratio is 14.39 based on the latest completed market-close snapshot from Sep 11, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is BDX's RSI?
BDX's 14-day RSI is 19.31 based on the latest completed market-close snapshot from Sep 11, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is BDX above its 50-day and 200-day moving averages?
BDX is 3.43% from its 50-day SMA and 3.73% from its 200-day SMA based on the latest completed market-close snapshot from Sep 11, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is BDX's next earnings date?
BDX's next earnings date is currently listed as Nov 5, 2026. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does BDX pay a dividend?
BDX's dividend yield is 0.02% based on the latest completed market-close snapshot from Sep 11, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.